This review discusses the significant progress made in the development of CNT/GO-based biosensors for disease biomarker detection. It highlights the specific applications of CNT/GO-based biosensors in the detection of various disease biomarkers, including cancer, cardiovascular diseases, infectious diseases, and neurodegenerative disorders. The superior performance of these biosensors, such as their high sensitivity, low detection limits, and real-time monitoring capabilities, makes them highly promising for early disease diagnosis. Moreover, the challenges and future directions in the field of CNT/GO-based biosensors are discussed, focusing on the need for standardization, scalability, and commercialization of these biosensing platforms. In conclusion, CNT/GO-based biosensors have demonstrated immense potential in the field of disease biomarker detection, offering a promising approach towards early diagnosis. Continued research and development in this area hold great promise for advancing personalized medicine and improving patient outcomes.

In the last several decades, cardiovascular diseases (CVDs) have emerged as a major hazard to human life and health. Conventional formulations for the treatment of CVD are available, but they are far from ideal because of poor water solubility, limited biological activity, non-targeting, and drug resistance. With the advancement of nanotechnology, a novel drug delivery approach for the treatment of CVDs has emerged: nano-drug delivery systems (NDDSs). NDDSs have shown significant advantages in tackling the difficulties listed above. Cytotoxicity is a difficulty with the use of non-destructive DNA sequences. NDDS categories and targeted tactics were outlined, as well as current research advancements in the diagnosis and treatment of CVDs. It’s possible that gene therapy might be included into nano-carriers in the delivery of cardiovascular medications in the future. In addition, the evaluation addressed the drug’s safety.